{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.051","pValueComment":"One-sided p-value.","statisticalComment":"Exact binomial test compares versus a proportion of 0.25.","statisticalMethod":"Exact binomial test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.7","upperLimit":"42.1","value":"32.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Overall response by Positron Emission Tomography-Computed Tomography (PET-CT) as defined by achieving complete response and/or partial response assessed by the investigator utilizing the modified Lugano Classification Revised Staging System for malignant lymphoma (Cheson, 2014).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.","reportingStatus":"POSTED","timeFrame":"Tumor assessment performed every 8 weeks for first 3 assessments, then every 12 weeks until documented disease progression (up to 46 months).","title":"Overall Response Rate Assessed by Investigator Based on PET-CT","type":"SECONDARY","unitOfMeasure":"percentage"}